Mifepristone for Labor Induction
Summary
The purpose of this trial is to explore mifepristone as an option for induction of labor at term by evaluating the efficacy of mifepristone use for cervical preparation. Since the Labor Induction versus Expectant Management in Low-Risk Nulliparous Women (ARRIVE) trial supporting that elective induction after 39 weeks decreases cesarean sections and morbidity, rates of elective term inductions are increasing. At Lucile Packard Children's Hospital at Stanford University specifically, approximately 40% of spontaneous vaginal deliveries follow induction of labor, with an average induction time of 20 hours. Previous studies have established the maternal and neonatal safety of mifepristone in term inductions, however, this study will assess the difference in overall time from induction to complete cervical dilation, delivery, and the total time on Labor and Delivery.
Timeline
- Start
- 2022-06-27
- Primary completion
- 2023-04-29
- Completion
- 2023-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mifepristone | Small molecule | 200 mg | Oral |
| Comparator | Misoprostol | Other / unclassified | 50 ug | Oral |
| Comparator | Misoprostol | Other / unclassified | 100 ug | Oral |
Indications
No indication recorded.